STOCK TITAN

Hims & Hers Health, Inc. Reports Third Quarter 2024 Financial Results

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Hims & Hers Health (NYSE: HIMS) reported strong Q3 2024 results with revenue reaching $401.6 million, up 77% year-over-year. The company achieved net income of $75.6 million and Adjusted EBITDA of $51.1 million. Subscriber base grew 44% to 2.0 million users. Monthly online revenue per average subscriber increased 24% to $67, while AOV rose 48% to $147. The company raised its full-year 2024 guidance, expecting revenue between $1.460-1.465 billion and Adjusted EBITDA of $173-178 million. Gross margin was 79%, and the company generated $85.3 million in operating cash flow.

Hims & Hers Health (NYSE: HIMS) ha riportato risultati solide per il terzo trimestre del 2024, con un fatturato pari a 401,6 milioni di dollari, in crescita del 77% rispetto all'anno precedente. L'azienda ha registrato un utile netto di 75,6 milioni di dollari e un EBITDA rettificato di 51,1 milioni di dollari. La base di abbonati è aumentata del 44%, raggiungendo 2,0 milioni di utenti. Il fatturato mensile online per abbonato medio è aumentato del 24%, arrivando a 67 dollari, mentre il valore medio degli ordini (AOV) è salito del 48%, raggiungendo 147 dollari. L'azienda ha rivisto al rialzo le previsioni per l'intero anno 2024, prevedendo un fatturato compreso tra 1,460 e 1,465 miliardi di dollari e un EBITDA rettificato di 173-178 milioni di dollari. Il margine lordo si è attestato al 79%, e l'azienda ha generato 85,3 milioni di dollari in flusso di cassa operativo.

Hims & Hers Health (NYSE: HIMS) reportó resultados sólidos para el tercer trimestre de 2024, con ingresos alcanzando 401,6 millones de dólares, un aumento del 77% comparado con el año anterior. La compañía logró un ingreso neto de 75,6 millones de dólares y un EBITDA ajustado de 51,1 millones de dólares. La base de suscriptores creció un 44%, alcanzando 2,0 millones de usuarios. Los ingresos mensuales en línea por suscriptor promedio aumentaron un 24%, hasta 67 dólares, mientras que el AOV subió un 48% a 147 dólares. La empresa elevó su guía para todo el año 2024, esperando ingresos entre 1.460 y 1.465 millones de dólares y un EBITDA ajustado de 173-178 millones de dólares. El margen bruto fue del 79%, y la compañía generó 85,3 millones de dólares en flujo de caja operativo.

Hims & Hers Health (NYSE: HIMS)는 2024년 3분기 실적을 발표하며 매출이 4억 1,600만 달러에 도달했다며, 전년 대비 77% 증가했다고 밝혔다. 이 회사는 7,560만 달러의 순이익5,110만 달러의 조정 EBITDA를 기록했다. 가입자 수는 44% 증가하여 200만 명에 달했다. 평균 가입자 기준 월 온라인 매출은 24% 증가하여 67달러에 달하고, 평균 주문 가치(AOV)는 48% 상승하여 147달러로 증가했다. 이 회사는 2024년 전체 연도 가이던스를 상향 조정하여 14억 6천만에서 14억 6천 5백만 달러의 매출과 1억 7천 3백만에서 1억 7천 8백만 달러의 조정 EBITDA를 기대하고 있다. 총 마진은 79%였으며, 운영 현금 흐름은 8천 530만 달러를 기록했다.

Hims & Hers Health (NYSE: HIMS) a annoncé des résultats solides pour le troisième trimestre 2024, avec un chiffre d'affaires atteignant 401,6 millions de dollars, en hausse de 77% par rapport à l'année précédente. L'entreprise a réalisé un revenu net de 75,6 millions de dollars et un EBITDA ajusté de 51,1 millions de dollars. La base d'abonnés a crû de 44%, atteignant 2,0 millions d'utilisateurs. Les revenus mensuels en ligne par abonné moyen ont augmenté de 24% à 67 dollars, tandis que la valeur moyenne des commandes (AOV) a augmenté de 48% à 147 dollars. L'entreprise a rehaussé ses prévisions pour l'année 2024, s'attendant à un chiffre d'affaires compris entre 1,460 et 1,465 milliard de dollars et à un EBITDA ajusté de 173-178 millions de dollars. La marge brute était de 79%, et l'entreprise a généré 85,3 millions de dollars de flux de trésorerie opérationnel.

Hims & Hers Health (NYSE: HIMS) hat starke Ergebnisse für das dritte Quartal 2024 vorgelegt, mit einem Umsatz von 401,6 Millionen Dollar, was einem Anstieg von 77% im Vergleich zum Vorjahr entspricht. Das Unternehmen erzielte einen Nettogewinn von 75,6 Millionen Dollar und ein angepasstes EBITDA von 51,1 Millionen Dollar. Die Abonnentenzahl wuchs um 44% auf 2,0 Millionen Nutzer. Der monatliche Online-Umsatz pro durchschnittlichem Abonnenten stieg um 24% auf 67 Dollar, während der durchschnittliche Bestellwert (AOV) um 48% auf 147 Dollar zunahm. Das Unternehmen erhöhte seine Prognose für das Gesamtjahr 2024 und erwartet einen Umsatz zwischen 1,460 und 1,465 Milliarden Dollar sowie ein angepasstes EBITDA von 173-178 Millionen Dollar. Die Bruttomarge lag bei 79%, und das Unternehmen erzielte 85,3 Millionen Dollar an operativem Cashflow.

Positive
  • Revenue grew 77% YoY to $401.6 million
  • Net income of $75.6 million vs loss in previous year
  • Adjusted EBITDA increased to $51.1 million from $12.3 million YoY
  • Subscriber base expanded 44% to 2.0 million
  • Average Order Value increased 48% to $147
  • Operating cash flow grew to $85.3 million from $25.2 million YoY
  • Raised full-year guidance for both revenue and EBITDA
Negative
  • Gross margin declined to 79% from 83% YoY

Insights

Exceptional Q3 results showcase HIMS's robust growth trajectory and successful execution. $401.6M revenue represents a staggering 77% YoY growth, while achieving $75.6M net income and $51.1M Adjusted EBITDA demonstrates strong profitability improvements. Key metrics are impressive across the board:

  • Subscriber base hit 2M, up 44% YoY
  • Average Order Value increased 48% to $147
  • Monthly revenue per subscriber grew 24% to $67

The raised FY2024 guidance to $1.46B revenue and $173-178M Adjusted EBITDA indicates management's confidence in sustained momentum. The GLP-1 weight loss offering is proving to be a significant growth catalyst while maintaining strong core business performance.

The telehealth platform's market positioning is strengthening significantly. The achievement of 2M subscribers with 1M using personalized solutions validates the company's strategy in democratizing healthcare access. The 79% growth in online revenue to $392.6M demonstrates strong digital adoption and scalability. The impressive 79% gross margin, though slightly down from last year's 83%, shows maintaining profitability while scaling rapidly. The $85.3M operating cash flow indicates a self-sustaining business model with strong unit economics. The platform's multi-condition approach and expanding personalization initiatives are creating powerful network effects and customer retention.

Revenue of $401.6 million, up 77% year-over-year in Q3 2024

Net income of $75.6 million; Adjusted EBITDA of $51.1 million in Q3 2024

Subscribers grew to 2.0 million, up 44% year-over-year in Q3 2024

Raises full year 2024 revenue guidance to a range of $1.460 billion to $1.465 billion and Adjusted EBITDA guidance to a range of $173 million to $178 million

SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2024 in a shareholder letter that is posted at investors.hims.com.

“Improving momentum in both the Hims and Hers brands delivered another strong quarter of growth and profitability,” said Andrew Dudum, co-founder and CEO. “Our execution against a strategy that brings customers convenient, transparent, and affordable access to care designed specifically for them is allowing us to reach millions of individuals across the country. In the third quarter, we eclipsed 2 million subscribers on our platform, with more than 1 million utilizing a personalized solution. These are significant milestones and confirm we are on a path to helping an American in every household feel great through the power of better health.”

Yemi Okupe, CFO, stated, “Our model is rapidly gaining scale, driving accelerating top line growth, improving profitability and strong cash flow. We are seeing this strength across our business. Our new weight loss offering is helping a growing number of people and providing an accelerant to what was already a robust trajectory. These strong underlying trends continued as subscriber growth excluding contributions from our compounded GLP-1 solutions increased 40% year-over-year, benefiting from improving brand awareness, broader personalization initiatives, and new customers accessing care for multiple conditions. Our ability to unlock access to high-quality, personalized care continues to expand, further instilling confidence that our model is positioned to help tens of millions of individuals over time.”

Key Business Metrics

(In Thousands, Except for Monthly Online Revenue per Average Subscriber and AOV, Unaudited)

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2024

 

2023

 

% Change

 

2024

 

2023

 

% Change

Subscribers (end of period)

 

 

2,047

 

 

1,426

 

44

%

 

 

2,047

 

 

1,426

 

44

%

Monthly Online Revenue per Average Subscriber

 

$

67

 

$

54

 

24

%

 

$

60

 

$

55

 

9

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Orders

 

 

2,664

 

 

2,222

 

20

%

 

 

7,652

 

 

6,378

 

20

%

AOV

 

$

147

 

$

99

 

48

%

 

$

126

 

$

95

 

33

%

Revenue

(In Thousands, Unaudited)

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2024

 

2023

 

% Change

 

2024

 

2023

 

% Change

Online Revenue

 

$

392,573

 

$

219,665

 

79

%

 

$

967,177

 

$

605,018

 

60

%

Wholesale Revenue

 

 

8,983

 

 

7,034

 

28

%

 

 

28,198

 

 

20,363

 

38

%

Total revenue

 

$

401,556

 

$

226,699

 

77

%

 

$

995,375

 

$

625,381

 

59

%

Third Quarter 2024 Financial Highlights

  • Revenue was $401.6 million for the third quarter of 2024 compared to $226.7 million for the third quarter of 2023, an increase of 77% year-over-year.
  • Gross margin was 79% for the third quarter of 2024 compared to 83% for the third quarter of 2023.
  • Net income was $75.6 million for the third quarter of 2024, which included a $60.8 million tax benefit related to the release of a tax valuation allowance, partially offset by current period tax expense. This compared to a net loss of $(7.6) million for the third quarter of 2023.
  • Adjusted EBITDA was $51.1 million for the third quarter of 2024 compared to $12.3 million for the third quarter of 2023.
  • Net cash provided by operating activities was $85.3 million for the third quarter of 2024 compared to $25.2 million for the third quarter of 2023.
  • Free Cash Flow was $79.4 million for the third quarter of 2024 compared to $19.3 million for the third quarter of 2023.

Reconciliations of Adjusted EBITDA and Free Cash Flow, non-GAAP measures, to net income (loss) and net cash provided by operating activities, respectively, their most comparable financial measures under generally accepted accounting principles in the United States (“U.S. GAAP”), have been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA and Free Cash Flow is also included below under the heading “Non-GAAP Financial Measures”.

Financial Outlook

Hims & Hers is providing the following guidance:

For the fourth quarter 2024, we expect:

  • Revenue of $465 million to $470 million.
  • Adjusted EBITDA of $50 million to $55 million, reflecting an Adjusted EBITDA margin of 11% to 12%.

For the full year 2024, we expect:

  • Revenue of $1.460 billion to $1.465 billion.
  • Adjusted EBITDA of $173 million to $178 million, reflecting an Adjusted EBITDA margin of 12%.

The guidance provided above constitutes forward-looking statements and actual results may differ materially. Refer to the “Cautionary Note Regarding Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

We have relied upon the exception in Item 10(e)(1)(i)(B) of Regulation S-K and have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net income (loss), because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net income (loss). See “Non-GAAP Financial Measures” for additional important information regarding Adjusted EBITDA.

Conference Call

Hims & Hers will host a conference call to review the third quarter 2024 results on November 4, 2024, at 5:00 p.m. ET. The conference call can be accessed by dialing +1 (888) 510-2630 for U.S. participants and +1 (646) 960-0137 for international participants, and referencing conference ID #1704296. A live audio webcast will be available online at investors.hims.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link.

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health.

We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.

For more information, please visit investors.hims.com.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believe,” “estimate,” “anticipate,” “expect,” “assume,” “imply,” “intend,” “plan,” “may,” “will,” “potential,” “project,” “predict,” “continue,” “could,” “confident,” “confidence,” or “should,” or, in each case, their plural, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line growth and profitability and our ability to attain our medium- and long-term financial targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, investments in innovation, the solutions accessible on our platform, and our infrastructure, and the underlying assumptions with respect to the foregoing; statements relating to events and trends relevant to us, including with respect to our regulatory environment, financial condition, results of operations, short- and long-term business operations, objectives, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, brand development, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies and leverage (including our fulfillment capabilities), the effect of any pricing decisions, changes in our product or offering mix, the timing and market acceptance of any new products or offerings (including compounded, generic and branded GLP-1 medications), the timing and anticipated effect of any pending acquisitions, the success of our business model, our market opportunity, our ability to scale our business, the growth of certain of our specialties, our ability to innovate on and expand the scope of our offerings and experiences, including through the use of data analytics and artificial intelligence, our ability to reinvest into the customer experience, and our ability to comply with the extensive, complex and evolving legal and regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations, and the effect or outcome of any litigation or governmental actions that may arise in relation to any such legal and regulatory requirement. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the “Risk Factors” section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Securities and Exchange Commission (the “Commission”).

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. These risks and others described in the “Risk Factors” section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Commission may not be exhaustive.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our most recently filed Annual Report on Form 10-K, our most recently filed Quarterly Report on Form 10-Q, and any of our subsequent filings with the Commission. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.

Key Business Metrics

“Online Revenue” represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve. Online Revenue is generated by selling directly to consumers through our websites and mobile applications. Our Online Revenue consists of products and services purchased by customers directly through our online platform. The majority of our Online Revenue is subscription-based, where customers agree to be billed on a recurring basis to have products and services automatically delivered to them.

“Wholesale Revenue” represents non-prescription product sales to retailers through wholesale purchasing agreements. Wholesale Revenue also includes non-prescription product sales to third-party platforms through consignment arrangements. In addition to being revenue generative and profitable, wholesale partnerships and consignment arrangements have the added benefit of generating brand awareness with new customers in physical environments and on third-party platforms.

“Subscribers” are customers who have one or more “Subscriptions” pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence. The Subscription billing cadence is typically defined as a number of days (for example, billed every 30 days or every 90 days), which are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscribers can cancel Subscriptions in between billing periods to stop receiving additional products and/or services and can reactivate Subscriptions to continue receiving additional products and/or services.

“Monthly Online Revenue per Average Subscriber” is defined as Online Revenue divided by “Average Subscribers”, which amount is then further divided by the number of months in a period. “Average Subscribers” are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2.

“Net Orders” are defined as the number of online customer orders minus transactions related to refunds, credits, chargebacks, and other negative adjustments. Net Orders represent transactions made on our platform during a defined period of time and exclude revenue recognition adjustments recorded pursuant to U.S. GAAP.

Average Order Value (“AOV”) is defined as Online Revenue divided by Net Orders (each as defined above).

CONDENSED CONSOLIDATED BALANCE SHEETS

(In Thousands, Except Share and Per Share Data, Unaudited)

 

 

September 30, 2024

 

December 31, 2023

 

 

 

 

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

165,518

 

 

$

96,663

 

Short-term investments

 

88,553

 

 

 

124,318

 

Inventory

 

49,110

 

 

 

22,464

 

Prepaid expenses and other current assets

 

23,194

 

 

 

21,608

 

Total current assets

 

326,375

 

 

 

265,053

 

Restricted cash

 

856

 

 

 

856

 

Goodwill

 

112,728

 

 

 

110,881

 

Property, equipment, and software, net

 

52,144

 

 

 

36,143

 

Intangible assets, net

 

44,818

 

 

 

18,574

 

Operating lease right-of-use assets

 

10,884

 

 

 

9,588

 

Deferred tax assets, net

 

54,318

 

 

 

 

Other long-term assets

 

138

 

 

 

91

 

Total assets

$

602,261

 

 

$

441,186

 

Liabilities and stockholders' equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

75,444

 

 

$

43,070

 

Accrued liabilities

 

43,224

 

 

 

28,972

 

Deferred revenue

 

32,184

 

 

 

7,733

 

Earn-out payable

 

 

 

 

7,412

 

Operating lease liabilities

 

1,793

 

 

 

1,281

 

Total current liabilities

 

152,645

 

 

 

88,468

 

Operating lease liabilities

 

9,565

 

 

 

8,667

 

Other long-term liabilities

 

 

 

 

22

 

Total liabilities

 

162,210

 

 

 

97,157

 

Commitments and contingencies

 

 

 

Stockholders' equity:

 

 

 

Common stock – Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 209,438,554 and 205,104,120 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of September 30, 2024 and December 31, 2023

 

22

 

 

 

21

 

Additional paid-in capital

 

707,962

 

 

 

712,307

 

Accumulated other comprehensive income (loss)

 

229

 

 

 

(124

)

Accumulated deficit

 

(268,162

)

 

 

(368,175

)

Total stockholders' equity

 

440,051

 

 

 

344,029

 

Total liabilities and stockholders' equity

$

602,261

 

 

$

441,186

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(In Thousands, Except Share and Per Share Data, Unaudited)

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2024

 

2023

 

2024

 

2023

Revenue

 

$

401,556

 

 

$

226,699

 

 

$

995,375

 

 

$

625,381

 

Cost of revenue

 

 

83,670

 

 

 

39,391

 

 

 

191,781

 

 

 

114,490

 

Gross profit

 

 

317,886

 

 

 

187,308

 

 

 

803,594

 

 

 

510,891

 

Gross margin %

 

 

79

%

 

 

83

%

 

 

81

%

 

 

82

%

Operating expenses:(1)

 

 

 

 

 

 

 

 

Marketing

 

 

182,284

 

 

 

116,076

 

 

 

457,759

 

 

 

320,540

 

Operations and support

 

 

47,519

 

 

 

31,609

 

 

 

127,719

 

 

 

87,018

 

Technology and development

 

 

21,092

 

 

 

12,270

 

 

 

55,070

 

 

 

34,822

 

General and administrative

 

 

44,617

 

 

 

35,907

 

 

 

119,739

 

 

 

97,564

 

Total operating expenses

 

 

295,512

 

 

 

195,862

 

 

 

760,287

 

 

 

539,944

 

Income (loss) from operations

 

 

22,374

 

 

 

(8,554

)

 

 

43,307

 

 

 

(29,053

)

Other income (expense):

 

 

 

 

 

 

 

 

Change in fair value of liabilities

 

 

 

 

 

(588

)

 

 

 

 

 

(1,056

)

Other income, net

 

 

1,219

 

 

 

2,226

 

 

 

6,113

 

 

 

6,342

 

Total other income, net

 

 

1,219

 

 

 

1,638

 

 

 

6,113

 

 

 

5,286

 

Income (loss) before income taxes

 

 

23,593

 

 

 

(6,916

)

 

 

49,420

 

 

 

(23,767

)

Benefit (provision) for income taxes

 

 

51,995

 

 

 

(651

)

 

 

50,593

 

 

 

(1,024

)

Net income (loss)

 

 

75,588

 

 

 

(7,567

)

 

 

100,013

 

 

 

(24,791

)

Other comprehensive income

 

 

397

 

 

 

125

 

 

 

353

 

 

 

144

 

Total comprehensive income (loss)

 

$

75,985

 

 

$

(7,442

)

 

$

100,366

 

 

$

(24,647

)

 

 

 

 

 

 

 

 

 

Net income (loss) per share attributable to common stockholders:

 

 

 

 

 

 

 

 

Basic

 

$

0.35

 

 

$

(0.04

)

 

$

0.47

 

 

$

(0.12

)

Diluted

 

$

0.32

 

 

$

(0.04

)

 

$

0.43

 

 

$

(0.12

)

Weighted average shares outstanding:

 

 

 

 

 

 

 

 

Basic

 

 

216,617,143

 

 

 

210,134,681

 

 

 

214,902,040

 

 

 

208,576,903

 

Diluted

 

 

235,069,539

 

 

 

210,134,681

 

 

 

233,149,762

 

 

 

208,576,903

 

______________

(1)

Includes stock-based compensation expense as follows (in thousands):

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2024

 

2023

 

2024

 

2023

Marketing

 

$

2,458

 

 

$

1,435

 

 

$

6,755

 

 

$

3,918

 

Operations and support

 

 

2,605

 

 

1,887

 

 

7,462

 

 

4,895

Technology and development

 

 

3,310

 

 

 

1,652

 

 

 

8,710

 

 

 

5,205

 

General and administrative

 

 

16,526

 

 

 

12,303

 

 

 

45,046

 

 

 

34,271

 

Total stock-based compensation expense

 

$

24,899

 

 

$

17,277

 

 

$

67,973

 

 

$

48,289

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In Thousands, Unaudited)

 

 

Nine Months Ended September 30,

 

2024

 

2023

Operating activities

 

 

 

Net income (loss)

$

100,013

 

 

$

(24,791

)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

 

 

 

Depreciation and amortization

 

11,027

 

 

 

6,857

 

Stock-based compensation

 

67,973

 

 

 

48,289

 

Change in fair value of liabilities

 

 

 

 

1,056

 

Net accretion on securities

 

(3,440

)

 

 

(4,034

)

Benefit for deferred taxes

 

(54,340

)

 

 

(30

)

Impairment of long-lived assets

 

114

 

 

 

429

 

Non-cash operating lease cost

 

1,875

 

 

 

1,412

 

Non-cash acquisition-related costs

 

 

 

 

2,264

 

Non-cash other

 

435

 

 

 

87

 

Changes in operating assets and liabilities:

 

 

 

Inventory

 

(26,295

)

 

 

(430

)

Prepaid expenses and other current assets

 

(1,535

)

 

 

(401

)

Other long-term assets

 

(47

)

 

 

(39

)

Accounts payable

 

35,052

 

 

 

4,401

 

Accrued liabilities

 

14,002

 

 

 

14,912

 

Deferred revenue

 

24,451

 

 

 

2,920

 

Operating lease liabilities

 

(1,761

)

 

 

(1,402

)

Earn-out payable

 

(2,825

)

 

 

 

Net cash provided by operating activities

 

164,699

 

 

 

51,500

 

Investing activities

 

 

 

Purchases of investments

 

(150,595

)

 

 

(136,415

)

Maturities of investments

 

189,292

 

 

 

117,334

 

Proceeds from sales of investments

 

725

 

 

 

1,574

 

Investment in website development and internal-use software

 

(8,730

)

 

 

(6,705

)

Purchases of property, equipment, and intangible assets

 

(17,135

)

 

 

(8,589

)

Acquisition of business, net of cash acquired

 

(15,399

)

 

 

 

Net cash used in investing activities

 

(1,842

)

 

 

(32,801

)

Financing activities

 

 

 

Proceeds from exercise of vested stock options

 

18,505

 

 

 

1,691

 

Payments for taxes related to net share settlement of equity awards

 

(33,096

)

 

 

(10,101

)

Repurchases of common stock

 

(78,034

)

 

 

 

Proceeds from employee stock purchase plan

 

1,622

 

 

 

898

 

Payments for acquisition-related earn-out consideration

 

(3,190

)

 

 

 

Net cash used in financing activities

 

(94,193

)

 

 

(7,512

)

Foreign currency effect on cash and cash equivalents

 

191

 

 

 

37

 

Increase in cash, cash equivalents, and restricted cash

 

68,855

 

 

 

11,224

 

Cash, cash equivalents, and restricted cash at beginning of period

 

97,519

 

 

 

47,628

 

Cash, cash equivalents, and restricted cash at end of period

$

166,374

 

 

$

58,852

 

Reconciliation of cash, cash equivalents, and restricted cash

 

 

 

Cash and cash equivalents

$

165,518

 

 

$

57,996

 

Restricted cash

 

856

 

 

 

856

 

Total cash, cash equivalents, and restricted cash

$

166,374

 

 

$

58,852

 

Supplemental disclosures of cash flow information

 

 

 

Cash paid for taxes

$

3,872

 

 

$

645

 

Non-cash investing and financing activities

 

 

 

Purchases of property and equipment included in accounts payable and accrued liabilities

$

704

 

 

$

5,237

 

Right-of-use asset obtained in exchange for lease liability

 

2,174

 

 

 

591

 

Issuance of common stock for acquisition-related earn-out consideration

 

1,396

 

 

 

 

Issuance of common stock and liabilities assumed in connection with acquisition of business

 

16,000

 

 

 

 

Non-GAAP Financial Measures

In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (which is a non-GAAP financial measure), Adjusted EBITDA margin (which is a non-GAAP ratio), and Free Cash Flow (which is a non-GAAP financial measure) each as defined below. We use Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow, when taken together with the corresponding U.S. GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow is helpful to our investors as they are used by management in assessing the health of our business, our operating performance, and our liquidity.

However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures or ratios differently or may use other financial measures or ratios to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow as tools for comparison. Reconciliations are provided below to the most directly comparable financial measures stated in accordance with U.S. GAAP. Investors are encouraged to review our U.S. GAAP financial measures and not to rely on any single financial measure to evaluate our business.

Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. “Adjusted EBITDA” is defined as net income (loss) before stock-based compensation, depreciation and amortization, acquisition and transaction-related costs (which includes (i) consideration paid for employee compensation with vesting requirements incurred directly as a result of acquisitions, inclusive of revaluation of earn-out consideration recorded in general and administrative expenses, and (ii) transaction professional services), impairment of long-lived assets, change in fair value of liabilities, interest income, and income taxes. “Adjusted EBITDA margin” is defined as Adjusted EBITDA divided by revenue.

Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted EBITDA. When evaluating our performance, you should consider Adjusted EBITDA in addition to, and not as a substitute for, other financial performance measures, including our net income (loss) and other U.S. GAAP results.

Net Income (Loss) to Adjusted EBITDA Reconciliation

(In Thousands, Unaudited)

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2024

 

2023

 

2024

 

2023

 

 

 

 

 

 

 

 

Revenue

$

401,556

 

 

$

226,699

 

 

$

995,375

 

 

$

625,381

 

 

 

 

 

 

 

 

 

Net income (loss)

 

75,588

 

 

 

(7,567

)

 

 

100,013

 

 

 

(24,791

)

Stock-based compensation

 

24,899

 

 

 

17,277

 

 

 

67,973

 

 

 

48,289

 

Depreciation and amortization

 

4,383

 

 

 

2,363

 

 

 

11,027

 

 

 

6,857

 

Acquisition and transaction-related costs

 

858

 

 

 

1,280

 

 

 

1,824

 

 

 

2,509

 

Impairment of long-lived assets

 

 

 

 

 

 

 

114

 

 

 

429

 

Change in fair value of liabilities

 

 

 

 

588

 

 

 

 

 

 

1,056

 

Interest income

 

(2,637

)

 

 

(2,342

)

 

 

(7,608

)

 

 

(6,428

)

(Benefit) provision for income taxes

 

(51,995

)

 

 

651

 

 

 

(50,593

)

 

 

1,024

 

Adjusted EBITDA

$

51,096

 

 

$

12,250

 

 

$

122,750

 

 

$

28,945

 

 

 

 

 

 

 

 

 

Net income (loss) as a % of revenue

 

19

%

 

 

(3

)%

 

 

10

%

 

 

(4

)%

Adjusted EBITDA margin

 

13

%

 

 

5

%

 

 

12

%

 

 

5

%

Free Cash Flow is a key performance measure that our management uses to assess our liquidity. Because Free Cash Flow facilitates internal comparisons of our historical liquidity on a more consistent basis, we use this measure for business planning purposes. “Free Cash Flow” is defined as net cash provided by operating activities, less purchases of property, equipment, and intangible assets and investment in website development and internal-use software in investing activities.

Some of the limitations of Free Cash Flow include (i) Free Cash Flow does not represent our residual cash flow for discretionary expenditures and our non-discretionary commitments, and (ii) Free Cash Flow includes capital expenditures, the benefits of which may be realized in periods subsequent to those in which the expenditures took place. In evaluating Free Cash Flow, you should be aware that in the future we will have cash outflows similar to the adjustments in this presentation. Our presentation of Free Cash Flow should not be construed as an inference that our future results will be unaffected by these cash outflows or any unusual or non-recurring items. When evaluating our performance, you should consider Free Cash Flow in addition to, and not as a substitute for, other financial performance measures, including our net cash provided by operating activities and other U.S. GAAP results.

Net Cash Provided By Operating Activities to Free Cash Flow Reconciliation

(In Thousands, Unaudited)

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2024

 

2023

 

2024

 

2023

Net cash provided by operating activities

 

$

85,267

 

 

$

25,191

 

 

$

164,699

 

 

$

51,500

 

Less: purchases of property, equipment, and intangible assets in investing activities

 

 

(3,342

)

 

 

(3,277

)

 

 

(17,135

)

 

 

(8,589

)

Less: investment in website development and internal-use software in investing activities

 

 

(2,539

)

 

 

(2,643

)

 

 

(8,730

)

 

 

(6,705

)

Free Cash Flow

 

$

79,386

 

 

$

19,271

 

 

$

138,834

 

 

$

36,206

 

 

Investor Relations

Bill Newby

Investors@forhims.com

Media Relations

Abby Reisinger

Press@forhims.com

Source: Hims & Hers

FAQ

What was Hims & Hers (HIMS) revenue in Q3 2024?

Hims & Hers reported revenue of $401.6 million in Q3 2024, representing a 77% increase year-over-year.

How many subscribers does HIMS have in Q3 2024?

Hims & Hers reached 2.0 million subscribers in Q3 2024, growing 44% compared to the previous year.

What is HIMS revenue guidance for full-year 2024?

Hims & Hers raised its full-year 2024 revenue guidance to $1.460-1.465 billion.

What was HIMS net income in Q3 2024?

Hims & Hers reported net income of $75.6 million in Q3 2024, which included a $60.8 million tax benefit.

Hims & Hers Health, Inc.

NYSE:HIMS

HIMS Rankings

HIMS Latest News

HIMS Stock Data

5.76B
184.42M
11.37%
65.88%
18.09%
Household & Personal Products
Services-offices & Clinics of Doctors of Medicine
Link
United States of America
SAN FRANCISCO